Clinical outcomes of COVID-19 in patients with liver cirrhosis - a propensity-matched analysis from a multicentric Brazilian cohort

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 15, 2025

Cirrhosis has been pointed out as a clinical entity that leads to worse prognosis in COVID-19 patients. However, this concept is controversial the literature. We aimed evaluate outcomes by comparing patients with cirrhosis those without Brazilian cohort. Data from 20,164 inpatients were collected 41 hospitals Brazil between March September 2020 and 2021 August 2022. compared 117 632 matched controls. A propensity score model was used adjust for potential confounding variables, incorporating some predictors: age, sex at birth, number of comorbidities, hospital admission, whether it an in-hospital manifestation COVID-19, admission year. Closeness defined being within 0.16 standard deviations logit score. The median age 61 (IQR 50–70) years old, 63.4% men. There no significant differences self-reported symptoms. Patients had lower hemoglobin levels (10.8 vs. 13.1 g/dl), platelets (127,000 200,000 cells/mm3), leukocyte counts, well C-reactive protein (63.0 76.0 p = 0.044) when They also higher mortality controls (51.3% 21.7%, < 0.001). frequencies intensive care unit 38.0%, 0.007), invasive mechanical ventilation (43.9% 26.6%, 0.001), dialysis (17.9% 11.1%, 0.038), septic shock (23.9% 14.9%; 0.015) institution palliative (19.7% 7.4%; This study shown significantly incidence severe outcomes, frequency Our findings underscore need these receive particular attention healthcare teams allocated resources.

Language: Английский

---

Impact of COVID-19 on preexisting comorbidities

Progress in molecular biology and translational science, Journal Year: 2025, Volume and Issue: unknown, P. 215 - 258

Published: Jan. 1, 2025

Language: Английский

---

A Comparative Analysis of Liver Injury Markers in Post-COVID Syndrome among Elderly Patients: A Prospective Study

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(4), P. 1149 - 1149

Published: Feb. 18, 2024

In the wake of global COVID-19 pandemic, understanding its prolonged impact on vulnerable populations has become a critical area investigation. This study aimed to elucidate distinctive post-acute sequelae SARS-CoV-2 infection (PASC) and liver injury in Romania's elderly population, hypothesizing unique demographic, clinical, healthcare factors influencing manifestation. A longitudinal design was employed, enrolling patients from Victor Babes Hospital for Infectious Diseases Pulmonology Timisoara, Romania. Participants were stratified into three groups based age Long COVID status. The focused variety biological parameters, including function tests, assess trajectory severity over six months post discharge. Involving 238 participants, revealed significant increase duration hospitalization those 65 (15.8 ± 8.2 days) compared younger (p < 0.001). Notably, exhibited marked elevation enzymes discharge, with median ΔALT ΔAST 24.1 U/L 30.2 U/L, respectively, suggesting ongoing Significant metabolic disruptions observed, ΔFasting glucose showing substantial decrease 21.1 mmol/L group pronounced reduction ΔGGT (16.7 U/L) ΔLDH (48.7 noted, indicating recovery reduced tissue damage Coagulation profiles fibrosis risk scores, particularly ΔFIB-4 ΔAPRI, also significantly improved complications. confirms hypothesis more severe PASC among Romanian population. improvements discharge suggest degree recovery, yet persistent alterations enzymes, metabolism, scores call continued monitoring tailored management strategies.

Language: Английский

---

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(4), P. 2212 - 2212

Published: Feb. 12, 2024

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related diverse extrapulmonary manifestations this pathology. liver was found be a relatively common organ, beyond the respiratory tract, affected by severe acute syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed essential role chronic (CLD) in general outcome infection. Present concerns field are direct hepatic caused COVID-19 and pre-existing disorders as risk factors for course Which mechanism has key phenomenon—previously existing disorder or failure SARS-CoV-2—is still not fully clarified. Alcoholic (ALD) constitutes another elucidated context Should toxic effects ethanol already developed cirrhosis its perceived causative triggering factor impairment patients? In face these discrepancies, we decided summarize whole picture infection, paying special attention ALD focusing on pathological pathways COVID-19, toxicity cirrhosis.

Language: Английский

---

Letter to the Editor: Progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease

Hepatology, Journal Year: 2023, Volume and Issue: 78(1), P. E14 - E15

Published: April 10, 2023

To the editor, We read article by Hartl et al1 with great intrigue. The study concluded that 20% of patients chronic liver disease (CLD) develop progressive cholestasis after severe acute respiratory syndrome coronavirus-2 infection and NAFLD/NASH metabolic risk factors are at particular for developing cholestatic failure and/or secondary sclerosing cholangitis COVID-19. Although this adds to growing evidence CLD likely have higher mortality rates due infection, several points worthy mention. First, in study, stratification was done according severity CLD. think an additional etiology is warranted, as many studies demonstrated independent factor adverse clinical outcomes. Two reviews published 2023 describe role morbidity infection. They conclude COVID-19 alcohol-associated NAFLD most frequently associated outcomes, whereas other etiologies such viral hepatitis HBV do not seem affect prognosis infection.2,3 Second, included only hospitalized patients, which can increase bias. Antiviral drugs, antibiotics, corticosteroids all used treat known cause injury. reported incidence DILI 25.4%.4 Additional analysis should been control potential confounders strengthen evidence. Third, between March 2020 July 2021. vaccine became globally available late 2020, vaccination status specified. Vaccination has resulted decreased hospitalization patients. However, underrepresented trials, on their efficacy safety these need be done.2 This failed provide any about either benefits or risks

Language: Английский

---

Clinical Outcomes of Covid-19 in Patients With Liver Cirrhosis - A Propensity-Matched Analysis From a Multicentric Brazilian Cohort

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 18, 2024

Background Cirrhosis has been pointed out as a clinical entity that leads to worse prognosis in COVID-19 patients. However, this concept is controversial the literature. We aimed evaluate outcomes by comparing patients with cirrhosis those without Brazilian cohort. Methods Data from 20,164 inpatients were collected 41 hospitals Brazil between March September 2020 and 2021 August 2022. compared 117 632 matched controls. A propensity score model was used adjust for potential confounding variables, incorporating some predictors: age, sex at birth, number of comorbidities, hospital admission, whether it an in-hospital manifestation admission year. Closeness defined being within 0.16 standard deviations logit score. Results The median age 61 (IQR 50–70) years-old, 63.4% men. There no significant differences self-reported symptoms. Patients had lower hemoglobin levels (10.8 vs 13.1 g/dl), platelets (127,000 200,000 cells/mm3), leukocytes counts, well C-reactive protein (63.0 76.0 p = 0.044) when controls.They also higher mortality controls (51.3% 21.7%, < 0.001). They frequencies intensive care unit 38.0%, 0.007), invasive mechanical ventilation (43.9% 26.6%, 0.001), dialysis (17.9% 11.1%, 0.038), septic shock (23.9% 14.9%; 0.015) institution palliative (19.7% 7.4%; Conclusions This study shown significantly incidence severe outcomes, frequency Our findings underscore need these receive particular attention healthcare teams allocated resources.

Language: Английский

---

Is Pulmonary Involvement a Distinct Phenotype of Post-COVID-19?

Biomedicines, Journal Year: 2023, Volume and Issue: 11(10), P. 2694 - 2694

Published: Oct. 2, 2023

(1) Background: COVID-19 infection often provokes symptoms lasting many months: most commonly fatigue, dyspnea, myalgia and mental distress symptoms. In this study, we searched for clinical features of post-COVID-19 condition (PCC) differences between patients with without pulmonary involvement. (2) Methods: A total 282 a mean age 57 years (SD +/− 12 years) underwent assessment up to weeks after recovery. The course acute disease, past medical history were gathered; function tests performed; radiographic studies assessed follow-up examinations conducted. Patients detectable lesions divided into separate groups. (3) Results: within the group more older (59 vs. 51 y.o.; p < 0.001) males (p = 0.002) that COVID-19-related hospitalization either ex- or active smokers median 20 pack-years. We also managed find correlations hypertension 0.01), liver failure 0.03), such as dyspnea 0.001), 0.04), headache 0.009), sleeplessness 0.046), (such FVC, TLCO, RV TLC; several basic laboratory (D-dimer, cardiac troponin, WBC, creatinine others). (4) Conclusions: Our results indicate initial involvement alters PCC, it can be used individualize approaches.

Language: Английский

---

COVID‐19 and cancer: Dichotomy of the menacing dilemma

MedComm – Oncology, Journal Year: 2023, Volume and Issue: 2(4)

Published: Nov. 30, 2023

Abstract The coronavirus disease 2019 (COVID‐19) pandemic brought about unprecedented challenges to global healthcare systems. Among the most vulnerable populations are cancer patients, who face dilemmas due their compromised immune systems and intricate interplay with severe acute respiratory syndrome 2 (SARS‐CoV‐2) virus. This comprehensive review delves into multifaceted relationship between COVID‐19 cancer. Through an analysis of existing literature clinical data, this unravels structural intricacies virus examines its profound implications for thereby bridging knowledge gap virology oncology. commences introduction regarding It then transitions a detailed examination SARS‐CoV‐2 variants such as Alpha (PANGO lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Omicron (B.1.1.529 lineage). Subsequently, insightful impact on major types (viz., Lung, Colon, Brain, gastrointestinal cancer) is elaborated. Finally, therapeutic avenues, oncological care, management discussed. nexus adds layer complexity patient emphasizing importance tailored approaches those grappling both conditions. Amid landscape defined by evolving viral strains, navigates through patients underscores significance integrating

Language: Английский

---